Literature DB >> 24398144

The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone.

Sehar Afreen1, Said Dermime2.   

Abstract

Over expression of B7-H1 (also named PDL-1 or CD 274) molecule in cancer has been linked to worse prognosis and resistance to anti-cancer therapies in several malignancies. In this review, we update on the expression of B7-H1 molecule in solid and hematological malignancies. We also describe the possible mechanisms by which this molecule inhibits/downregulates the immune response to cancer cells. Finally, we highlight current and future potential therapeutic strategies that can be further developed to target this molecule.
Copyright © 2013 King Faisal Specialist Hospital & Research Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  B7-H1; CD 274; Cancer prognosis; Immune escape; PD-L1; Targeted therapy

Mesh：

Substances：

Year:  2014        PMID： 24398144     DOI： 10.1016/j.hemonc.2013.09.005

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  42 in total

1.  BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

Authors:  Trevor E Angell; Melissa G Lechner; Julie K Jang; Adrian J Correa; Jonathan S LoPresti; Alan L Epstein
Journal:  Thyroid       Date:  2014-07-15       Impact factor: 6.568

2.  Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.

Authors:  Hai-Xia Qu; Li-Ping Zhao; Shu-Hui Zhan; Chang-Xin Geng; Lin Xu; Yong-Ning Xin; Xiang-Jun Jiang
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 3.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

4.  Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.

Authors:  Zhun Wang; Shuanghe Peng; Hui Xie; Linpei Guo; Qiliang Cai; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Clin Exp Med       Date:  2018-01-23       Impact factor: 3.984

5.  B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer.

Authors:  Lujun Chen; Haifeng Deng; Mingyang Lu; Bin Xu; Qi Wang; Jingting Jiang; Changping Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 6.  The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.

Authors:  Yaoan Wen; Yeda Chen; Xiaolu Duan; Wei Zhu; Chao Cai; Tuo Deng; Guohua Zeng
Journal:  Clin Exp Med       Date:  2019-08-12       Impact factor: 3.984

Review 7.  Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.

Authors:  Feng Xu; Lingling Xu; Qian Wang; Guangyu An; Guosheng Feng; Fuquan Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 8.  Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.

Authors:  Theodore S Nowicki; Jennifer L Anderson; Noah Federman
Journal:  Pediatr Res       Date:  2015-11-23       Impact factor: 3.756

9.  Differential induction of PD-1/PD-L1 in Neuroimmune cells by drug of abuse.

Authors:  Vikas Mishra; Heather Schuetz; James Haorah
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2015-08-15

Review 10.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.

Authors:  Zhong-Yi Dong; Si-Pei Wu; Ri-Qiang Liao; Shu-Mei Huang; Yi-Long Wu
Journal:  Tumour Biol       Date:  2016-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.